Advances in Smart and Innovative Nanoparticles for Precision Tumor Therapy: Design, Delivery, Immune Modulation, and Clinical Translation
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Methods".
Deadline for manuscript submissions: 27 February 2026 | Viewed by 478
Special Issue Editors
Interests: drug development; lipid nanoparticles; immunotherapy; cancer treatment; nanomedicine
Interests: polymer chemistry; nanomedicine; biodegradable polymers; targeted drug delivery; gene delivery; vaccine delivery; nanotechnology; cancer therapy; biomaterials
Special Issue Information
Dear Colleagues,
Recent advances in nanotechnology have revolutionized cancer therapy by enabling the development of smart and innovative nanoparticles designed for precision tumor targeting. These nanoplatforms integrate advanced materials, stimuli-responsive systems, and biomimetic strategies to enhance drug delivery, improve tumor penetration, and minimize off-target toxicity. Beyond conventional cytotoxic payloads, next-generation nanoparticles incorporate immunomodulatory agents to reprogram the tumor microenvironment and synergize with immunotherapies. Innovations in design, including ligand-mediated targeting, controlled release mechanisms, and real-time theranostic capabilities, are bridging the gap between preclinical success and clinical translation. Collectively, these technologies hold the potential to transform oncology by offering more effective, personalized, and durable therapeutic outcomes for patients with challenging malignancies.
Dr. Hari Krishna Reddy Rachamala
Dr. Naga Malleswara Rao Nakka
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- smart nanoparticles
- tumor-targeted drug delivery
- immune modulation
- stimuli-responsive nanocarriers
- clinical translation in oncology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
